iPSirius

iPSirius SAS, [pronounced ip-Sirius], is a French headquartered immuno-oncology firm, seeking to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patient... Read more